Curative Biotechnology, Inc. (CUBT) Announces December 2nd IPO

Curative Biotechnology, Inc. (CUBT) expects to raise $8 million in an initial public offering (IPO) on Friday, December 2nd, IPO Scoop reports. The company will issue 1,300,000 shares at a price of $6.00 per share.

The company has a market cap of $18.5 million.

Aegis Capital Corp. served as the underwriter for the IPO.

Curative Biotechnology, Inc. provided the following description of their company for its IPO: “(Note: This is NOT an IPO. Curative Biotechnology, Inc. revived its NYSE-American uplisting from the OTC Pink Market as a unit deal on Nov. 7, 2022: a public offering of 1.33 million units – stock and warrants – at $6.00 per unit, based on a 1-for-400 reverse stock split ratio. Its previous NYSE-American uplisting and public offering – a stock-only offering – was withdrawn on Oct. 31, 2022; the stock-only offering’s terms had called for 1.55 million shares at $5.15.) We are a life science company seeking to develop, in-license, sub-license or otherwise acquire early mid- or late-stage assets in the therapeutic and medical device areas. We focus on development stage products that can be acquired at advantageous valuations and terms and assets that we believe either already have or possess the possibility for significant intellectual property. Additionally, we seek to acquire assets that lend themselves to an accelerated clinical and/or regulatory development path. As of the date of this prospectus, we have not submitted any INDs with the FDA for any of our product candidates. We have licensed four (4) pre-clinical assets and are initially focused on the following four (4) indications: (i) Rabies, (ii) Glioblastoma, (iii) Age-Related Macular Degeneration, and (iv) COVID-19 vaccinations in patients with kidney failure. Historically, we have devoted our efforts and financial resources primarily to our general operations and the research and acquisition of our product candidates.  Based on our cash position, and assuming the receipt of approximately $7.0 million in net proceeds from this offering, we anticipate utilizing the funds for the repayment of our outstanding secured convertible promissory note issued in March 2022, pre-clinical research, including toxicology, pharmacokinetics, and safety studies in animals and manufacturing in anticipation for the regulatory submissions of one or more investigational new drug application or IND with the United States Food and Drug Administration (FDA). If any of our proposed INDs are approved, we will utilize the balance of the funds for manufacturing (for certain of our therapeutics as described herein), to conduct our clinical trials (for certain of our therapeutics as described herein) and for general corporate working capital purposes. It is still too early to determine if our product candidates will meet the requirements for IND approval. Our development pipeline focuses on three (3) therapeutic areas: infectious diseases, oncology, and degenerative eye disease. Under these therapeutic areas, we are focusing on four (4) programs: (i) Rabies, (ii) COVID 19 Vaccines in Kidney Failure Patients, (iii) Glioblastoma, and (iv) Degenerative Eye Diseases Even if we are able to raise the net proceeds described above, management has determined that it will still need to make a determination on what indications within those four (4) programs to pursue as we will not have sufficient capital to pursue all of the below indications.   Therapeutic Area   Candidate   Indication   Research and Pre-Clinical   Phase 1   Phase 2   Phase 3 Infectious Diseases   IMT505   Rabies    (1)                                       Infectious Diseases   COVID Vaccine with IMT504 Adjuvant   COVID 19 in Kidney Failure Patients    (2)                                       Oncology   CUBT906- CD56 Monoclonal Antibody ADC   Glioblastoma    (2)                                       Degenerative Eye Disease   Metformin Reformulation   Age-Related Macular Degeneration    (1)                 (1) Each of these therapeutics have undergone certain toxicology and pharmacokinetics animal studies. Please see further description in “Product Development” below for a further description of the development of each indicated therapeutic.   (2) Each of these therapeutics have not undergone pre-clinical development. Please see further description in “Product Development” below for a further description of the development of each indicated therapeutic.     “.

Curative Biotechnology, Inc. was founded in 1995 and has 4 employees. The company is located at 1825 NW Corporate Blvd, Suite 110 Boca Raton, FL 33431 and can be reached via phone at (561) 907-8990 or on the web at

Receive News & Ratings for Curative Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curative Biotechnology Inc. and related companies with's FREE daily email newsletter.